Deutsche Bank downgrades Novartis to Hold after second clinical setback
Deutsche Bank downgraded Novartis to Hold from Buy, cutting its price target to 120 Swiss francs from 140 francs. The move follows clinical setbacks for del-desiran and pelacarsen, raising concerns about the company's deal-making. Analyst Emmanuel Papadakis noted these setbacks create a gap in Novartis's pipeline and increase business development risk. Novartis shares fell over 10% on Tuesday.
How this was made
The 30-second read
Why it matters
The downgrade and price‑target cut triggered a >10% share decline, indicating immediate market impact.
Market read
The downgrade is a primary catalyst for short‑term price movement in Novartis and may influence sector sentiment.
What to watch
Upcoming data on remibrutinib could offset short‑term weakness if results are positive.
Background
Deutsche Bank cited a second clinical disappointment and concerns over Novartis' deal‑making track record.
Ticker impact
Deutsche Bank downgraded Novartis to Hold, cut price target to 120 CHF and shares fell more than 10% on the same day.
downward pressure, potential further decline in short term
Analyst downgrade with a sizable price‑target reduction and a >10% intraday drop signals fresh bearish sentiment.
Market effects
Potential ripple across pharma sector as peers may face heightened scrutiny on deal‑making and pipeline setbacks.
European markets may see modest pullback in healthcare stocks.
Limited to pharma/biotech investors; no broad macro effect.
Counterpoint
Some investors may view the downgrade as over‑reaction given long‑term pipeline strength.
Key entities
- companyNovartis AG
Swiss pharmaceutical giant
- analystDeutsche Bank
Issued the downgrade and target reduction
